Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2

Status

Completed 72Terminated 17Recruiting 13Active not recruiting 6Withdrawn 3Unknown 2Not yet recruiting 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Classical hematology 3Myeloid 2Lymphoid 2

Conditions

Breast Neoplasms 111Carcinoma, Non-Small-Cell Lung 102Prostatic Neoplasms 66Multiple Myeloma 64Neoplasm Metastasis 63Colorectal Neoplasms 63Neoplasms 59Lung Neoplasms 52Leukemia, Myeloid, Acute 41Carcinoma, Hepatocellular 41Recurrence 40Lymphoma 40Leukemia, Lymphocytic, Chronic, B-Cell 36Pancreatic Neoplasms 34Melanoma 34Head and Neck Neoplasms 27Glioblastoma 26Rectal Neoplasms 25Ovarian Neoplasms 25Lymphoma, Large B-Cell, Diffuse 25Leukemia 24Brain Neoplasms 24Squamous Cell Carcinoma of Head and Neck 23Hematologic Neoplasms 23Carcinoma, Renal Cell 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Myelodysplastic Syndromes 20Colonic Neoplasms 20Triple Negative Breast Neoplasms 19Lymphoma, Non-Hodgkin 19

Interventions

magrolimab 1Radiotherapy 1Peripheral Blood Stem Cell Transplantation 1Methotrexate 1Daunorubicin 1Cytarabine 1Cyclosporine 1Cyclophosphamide 1CPX-351 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Withdrawn × Anemia, Refractory, with Excess of Blasts × Clear all
NCT05829434 2024-02-12

MAGROLIC

University of Leipzig

Phase 2 Withdrawn
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute

NCT02765997 2017-12-05

StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies

Masonic Cancer Center, University of Minnesota

Phase 2 Withdrawn
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00081055 2014-12-04

OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies

Mesoblast, Ltd.

Phase 2 Withdrawn
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡